Rhythm Follow-Up
Overall freedom from ATAs was 94% (120/128), 83% (53/64), and 88%
(35/40) at 1, 5, and 7 years, respectively (Figure 1). Freedom from ATAs
and AADs was 87% (111/128), 69% (44/64), and 68% (27/40) at the same
time points. At each timepoint, the percentage of patients on warfarin
was 23% (30/133), 30% (20/67), and 32% (12/37), respectively. By
competing risks analysis to first ATA recurrence, the probability of
remaining alive and free of ATAs was estimated to be 91%, 76%, and
63% at follow-up years 1, 5, and 8, respectively (Figure 2 and Table
5). The estimated incidence of first ATA recurrence was 7%, 18%, and
25%, respectively. Estimated mortality at these time points was 2%,
6%, and 12%, respectively. Amongst patients who did have recurrence of
ATA, the median number of recurrences was 2 (IQR 1-3) over the entire
follow-up period, with 61% (22/36) of these patients having only 1-2
recurrences.